サイクリンE-CDK2キナーゼの活性が細胞のアンカレージに依存していること
1La Jolla Cancer Research Foundation, Cancer Center, CA 92037, USA.
まとめ
ほとんどの非悪性細胞は,成長のために結合を必要とし,癌では依存性が失われます. この研究は,細胞サイクル進行に不可欠なサイクリンE-CDK2複合体の活性が,懸浮細胞で抑制され,アンカージ依存を潜在的に説明することを明らかにしています.
科学分野:
- 細胞生物学 細胞生物学
- 分子生物学は分子生物学である.
- がん研究 がん研究
背景:
- 非悪性細胞はアンカージに依存し,成長と生存のために基板の結合を必要とします.
- 腫瘍性変異は,この重要なアンカージ依存性の喪失につながります.
- 細胞サイクルのG1-S移行は,主要なタンパク質複合体によって調節されます.
研究 の 目的:
- 固定系に依存した細胞成長におけるサイクリンE-CDK2複合体の役割を調査する.
- 腫瘍性変異が,細胞結合に関連してサイクリンE-CDK2の活性にどのように影響するか判断する.
- アンカレージ依存の背後にある分子メカニズムを解明する.
主な方法:
- 添付状態および懸浮状態のヒト線維芽細胞の細胞培養.
- 細胞サイクル中のサイクリンE-CDK2複合体の活性に関する分析.
- CDK2阻害体発現とCDK2のリン酸化状態の評価.
主要な成果:
- サイクリンE-CDK2複合体の活性化は,付着した線維芽細胞のG1期末に発生したが,懸浮細胞には存在しなかった.
- トランスフォーメーションされた線維芽細胞は,結合に関係なく,構成サイクリンE-CDK2複合体の活性を示した.
- サスペンド細胞は,トリオニン-160.0でCDK2阻害剤の増加とCDK2リン酸化の減少を示した.
結論:
- 懸浮細胞におけるサイクリンE-CDK2の活性抑制は,アンカレージ依存症の重要な要因である.
- サイクリンE-CDK2の活性を調節することは,正常な細胞成長制御に不可欠です.
- これらのメカニズムの理解は,がんの発達と治療戦略の洞察を提供することができます.
さらに関連する動画
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
関連する概念動画
Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
